<SEC-DOCUMENT>0001659617-20-000068.txt : 20200319
<SEC-HEADER>0001659617-20-000068.hdr.sgml : 20200319
<ACCEPTANCE-DATETIME>20200319161611
ACCESSION NUMBER:		0001659617-20-000068
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200319
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200319
DATE AS OF CHANGE:		20200319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Moleculin Biotech, Inc.
		CENTRAL INDEX KEY:			0001659617
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				474671999
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37758
		FILM NUMBER:		20728723

	BUSINESS ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
		BUSINESS PHONE:		713-300-5160

	MAIL ADDRESS:	
		STREET 1:		5300 MEMORIAL DRIVE
		STREET 2:		SUITE 950
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77007
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k123119earningsrelea.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8E6F40016FA053BBBE31E3E3391DA350"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 19, 2020</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MOLECULIN BIOTECH, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact Name of Registrant as Specified in its Charter)</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DELAWARE</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-37758</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47-4671997</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction of Incorporation or Organization)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File No.)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5300 MEMORIAL DRIVE, SUITE 950, HOUSTON TX 77007</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices and zip code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(713) 300-5160</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Former name or former address, if changed from last report)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">see </font><font style="font-family:inherit;font-size:10pt;">General Instruction A.2. below):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;padding-bottom:32px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:432px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company [X]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s05A1742513545F56AF8B780C21894A1B"></a></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 2.02  Results of Operations and Financial Condition.</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:11pt;">On March 19, 2020, Moleculin Biotech, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the year ended December 31, 2019 and recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit No.&#160;&#160;&#160;&#160;Description</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials123119q42.htm"><font style="font-family:inherit;font-size:11pt;">99.1</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><a style="text-decoration:underline;color:#0000FF;font-size:11pt;-sec-extract:exhibit;" href="exh991-financials123119q42.htm"><font style="font-family:inherit;font-size:11pt;">Press release dated March 19, 2020</font></a></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:192px;text-indent:-96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNATURE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:justify;padding-left:336px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">MOLECULIN BIOTECH, INC.</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:336px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;">Date:  March 19, 2020</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jonathan P. Foster</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jonathan P. Foster</font></div><div style="line-height:120%;text-align:justify;padding-left:336px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Chief Financial Officer  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s78244516689E5B94BBDE89A65A17F6CA"></a></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit No.</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Description</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><a style="font-family:inherit;font-size:11pt;" href="exh991-financials123119q42.htm"><font style="font-family:inherit;font-size:11pt;">99.1</font></a><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><a style="font-family:inherit;font-size:11pt;" href="exh991-financials123119q42.htm"><font style="font-family:inherit;font-size:11pt;">Press release dated March 19, 2020</font></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;text-indent:312px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"></font><font style="font-family:inherit;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh991-financials123119q42.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBACA9C1461E258D3AA916BFB64A3217B"></a></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Exhibit 99.1</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="moleculin-logo_horiza25.jpg" alt="moleculin-logo_horiza25.jpg" style="height:60px;width:226px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:22pt;"><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#32;&#32;&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:22pt;color:#2f5496;font-weight:bold;">Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">HOUSTON, March 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced its financial results for the year ended December 31, 2019 and provided a business update.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">Management Discussion</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Walter Klemp, Chairman and CEO of Moleculin, stated, "2019 marked a pivotal year for Moleculin, as we achieved several key milestones in our three core technologies and six oncology drug candidates, strengthened our financial position, and bolstered our leadership team. Notably, we are extremely excited by the progress we made advancing our lead candidate, Annamycin, a &#8216;next generation anthracycline&#8217; demonstrating little to no cardiotoxicity. In the recently completed Phase 1 portion of our US Phase 1/2 clinical trial in AML, Annamycin met its primary endpoint and demonstrated a clean safety profile with no evidence of cardio-toxicity when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA. These findings were consistent with an independent review of Annaymcin, in which the independent expert concluded that he &#8216;does not see evidence of cardio-toxicity.&#8217; We are looking forward to further advancing this trial in 2020, as the FDA has already granted Annamycin Fast Track status and Orphan Drug Designation for AML. We plan to discuss with the FDA a plan to accelerate our approval pathway for a pivotal Phase 2 trial by relying on our European trial to establish a recommended Phase 2 dose, which we believe will be the fastest and most efficient way for us to enter Phase 2. We also look forward to filing an Investigational New Drug (IND) application for the treatment of tumor metastases to the lung in 2020</font><font style="font-family:Times New Roman;font-size:11pt;">."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Mr. Klemp continued, "We are also pleased by the progress made in both our WP1066 and WP1122 programs. In our WP1066 portfolio, Emory University received FDA approval for their IND status request for our STAT3 Inhibitor in a pediatric brain tumor clinical trial. This approval enables us to explore a new approach for treating pediatric brain cancer. Pre-clinical research at Emory demonstrated WP1066&#8217;s significant anti-tumor effect on medulloblastoma cell lines, and we are very encouraged to continue to explore this potential solution for treating this rare condition. Additionally, we reported positive data from the Phase 1 &#8216;proof-of-concept&#8217; clinical trial with WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL), which demonstrated a median reduction of 56% in skin cancer lesions. We also made great strides within our WP1122 portfolio where we began preclinical testing of a new approach to Pancreatic cancer, by attacking cancer through inhibiting tumor metabolism.</font><font style="font-family:Calibri,sans-serif;font-size:12pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">"</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Mr. Klemp concluded, "We are excited to build off the tremendous progress made in 2019 across our entire drug portfolio. We believe we are well positioned to continue the momentum in 2020 and look forward to the upcoming WP1066 trial at Emory University, advancing WP1220 into a Phase 2 clinical trial, and the </font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 1</font><font style="font-family:Arial;font-size:10pt;">&#32;of 5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">potential accelerated FDA approval pathway and Phase 2 trial of Annamycin. And, this momentum has taken on a new dimension with our recent announcement of our agreement with UTMB to test WP1122 for antiviral properties on many viruses, including Coronavirus. We continue to work diligently towards our near-term goals of delivering on Phase 2 clinicals trial for WP1220 and our &#8216;next generation anthracycline,&#8217; Annamycin.  We look forward to sharing our progress throughout the year."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">Recent Milestones and Accomplishments:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Next Generation Anthracycline - Annamycin</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Received positive independent report confirming absence of cardiotoxicity (unlike currently approved anthracyclines)</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Announced positive results and successful completion of the Phase 1 portion of the AML Phase 1/2 trial in the US and plans to seek accelerated FDA approval for pivotal Phase 2 trial in AML</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Found to be active against tumor metastases to the lung in pre-clinical testing </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Confirmed anti-tumor efficacy of Annamycin in AML through new animal data</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Expanded production to support positive clinical activity</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Received FDA Fast Track designation and filed for new patents covering the production and reconstitution of Annamycin</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Immune/Transcription Modulators - WP1066 Portfolio</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Emory University received FDA Approval of IND for STAT3 inhibitor in Investigator Initiated Clinical Trial</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Filed for patent protection on behalf of MD Anderson covering combination of immune-stimulating/transcriptional modulator, including combination with radiation therapy</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Received Emory University Clinical Trial Review Committee approval in pediatric brain tumor trial</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Presented preclinical pancreatic cancer data at American Association for Cancer Research Annual Meeting</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Received Orphan Drug Designation from FDA</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Metabolism/Glycosylation Inhibitors - WP1122 Portfolio</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Final data from Phase 1 proof-of-concept clinical trial for the treatment of cutaneous T-cell lymphoma</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Began preclinical testing of new approach to Pancreatic cancer, opportunity to attack cancer by inhibiting tumor metabolism</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Entered into an agreement with University of Texas Medical Branch at Galveston (UTMB) to conduct research on WP1122, and other molecules of the Company, for antiviral properties against a range of viruses, including Coronavirus</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Corporate Strategy</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Entered into sublicense agreement with WPD Pharmaceuticals requiring WPD to provide a minimum of $4 million in development expenditures over a four-year period</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Appointed Dr. Martin Tallman, Chief of Leukemia of Memorial Sloan Kettering Cancer Center, and Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, to Science Advisory Board</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Appointed Dr. Hongbo Zhai, former Senior Faculty and Supervisor of Postdoctoral Fellow at University of California San Francisco, to Science Advisory Board</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Calibri,sans-serif;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">Anticipated 2020 Milestones</font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 2</font><font style="font-family:Arial;font-size:10pt;">&#32;of 5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">First patient treated in the Phase 1 clinical trial with WP1066 for the treatment of pediatric brain tumors at Emory University</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">IND submission for Annamycin for the treatment of tumor metastases to the lung</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Pre-IND Meeting with FDA/EMA concerning a Phase 2 clinical trial with WP1220 for the treatment of CTCL </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">File IND/CTA for a Phase 2 clinical trial with WP1220 for the treatment of CTCL </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">FDA End of Phase 1 meeting for Annamycin in AML</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Achieving an MTD or a dose level at or above 300 mg/m</font><font style="font-family:Calibri,sans-serif;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">2 </sup></font><font style="font-family:Calibri,sans-serif;font-size:11pt;">in EU AML Phase 1/2 trial for Annamycin</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Benefit from non-dilutive financial funding for additional clinical trials</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Calibri,sans-serif;font-size:14pt;font-weight:bold;">Financial Results for the Year Ended December 31, 2019</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Research and development ("R&amp;D") expense was $11.0 million and $9.7 million for the years ended December 31, 2019 and 2018, respectively. The increase in R&amp;D of approximately $1.3 million mainly relates to: increased clinical trial activity (2 drugs in 3 clinical trials in 2018, versus 3 drugs in 4 clinical trials in 2019) including the manufacturing of additional drug product and the issuance of common stock for $0.5 million, related to the exercise of the option to reacquire certain license rights in Germany under the Dermin License Agreements. These increases were offset by a reduction in various other R&amp;D expenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">General and administrative ("G&amp;A") expense was $6.3 million and $5.2 million for the years ended December 31, 2019 and 2018, respectively. The increase in G&amp;A of approximately $1.1 million was mainly attributable to an increase in payroll costs for additional finance and office staff, stock-based compensation expense for vested warrants issued to a consultant, and annual employee stock options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">The net loss for the year ended December 31, 2019 was $13.2 million, which included non-cash expenses of approximately $1.5 million of stock-based compensation in 2019 as compared to $1.1 million in 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">As of December 31, 2019, we had cash and cash equivalents of $10.7 million and prepaid expenses and other of $2.7 million. We also had $2.2 million of accounts payable and $1.4 million of accrued expenses. A significant portion of the accounts payable and accrued expenses are due to work performed in relation to our clinical trials. For the years ended December 31, 2019 and 2018, we used approximately $17.2 million and $12.2 million of cash in operating activities, respectively, which represents cash outlays for research and development and general and administrative expenses in such periods. The increase in 2019 reflects the increase in clinical and preclinical activity over 2018. For the year ended December 31, 2019, net proceeds from financing activities were $20.9 million, predominately from the sale of our common stock and warrants. In 2018, approximately $12.0 million was raised predominately through the sale of shares of common stock and the exercise of warrants. Cash used in investing activities for the year ended December 31, 2019 was approximately $0.05 million primarily for the purchases of employee computer equipment and office furniture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">We believe that our cash resources as of December 31, 2019, along with the additional funding received subsequent to year-end, will be sufficient to meet our projected operating requirements towards the end of the third quarter of 2020. This expectation does not consider unplanned preclinical and clinical activity, additional funding, including but not limited to, equity issuances including the use of the Lincoln Park or ATM facilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 3</font><font style="font-family:Arial;font-size:10pt;">&#32;of 5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">About Moleculin Biotech, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of oncology drug candidates for the treatment of highly resistant tumors. The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">For more information about the Company, please visit http://www.moleculin.com.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;">Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:11pt;">the ability of Moleculin to successfully recruit sufficient patients to complete its current clinical trials; the ability of Moleculin to be permitted by the FDA to accelerate its approval pathway for a pivotal Phase 2 trial by relying on its European trial to establish a recommended Phase 2 dose; and the ability of Moleculin to file an IND for the treatment of cancer metastases to the lung in 2020. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin Biotech has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#444444;font-weight:bold;">Contacts</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#444444;">James Salierno / Carol Ruth</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#444444;">The Ruth Group</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#444444;">646-536-7028 / 7000</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#0264b1;text-decoration:underline;">jsalierno@theruthgroup.com</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;color:#0264b1;text-decoration:underline;">cruth@theruthgroup.com</font></div><div style="line-height:174%;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:174%;text-align:center;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;font-weight:bold;">-- FInancial tables on the following page --</font></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 4</font><font style="font-family:Arial;font-size:10pt;">&#32;of 5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Moleculin Biotech, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unaudited Condensed Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">December 31</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">10,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">7,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">2,749</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">840</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">13,484</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">7,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Furniture and equipment, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">463</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">11,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">11,148</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Operating lease right-of-use asset</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total Assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">25,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">19,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Current Liabilities:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Accounts payable and accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">3,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">3,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Warrant liability - current</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">180</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;Total current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">3,570</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">3,878</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Operating lease liability - long-term, net of current portion</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Deferred rent - long-term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Warrant liability - long term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">5,818</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">1,328</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">9,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">5,313</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Total Stockholders' Equity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">15,571</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">14,272</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;Total Liabilities and Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">25,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">19,585</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Year Ended December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">(in thousands, except share and per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Operating Expenses:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Research and development</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">11,013</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">9,728</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">General and Administrative and  depreciation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">6,511</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">5,297</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Total operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">17,524</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">15,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Loss from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(17,524</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(15,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Other income (expense):</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Gain from change in fair value of warrant liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">4,062</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">3,185</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Interest income, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">13</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Net Loss before taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(13,434</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(11,876</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Income tax benefit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(13,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(11,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Net loss per common share - basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(0.32</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">(0.46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">Weighted average common shares outstanding - basic and diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">40,721,406</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">25,904,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="font-family:Times New Roman;"><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Page 5</font><font style="font-family:Arial;font-size:10pt;">&#32;of 5</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>moleculin-logo_horiza25.jpg
<TEXT>
begin 644 moleculin-logo_horiza25.jpg
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M>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X #D%D;V)E &3
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M$0,1 #\ O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M7S*57L)HY%:GWS6N5S?"CD14Z3+H\ Z(
M
M
M
M
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M\+'.3PEK\K9XRCG:T^.Y4Q"UOH41%<D;TXV5W=I$M)(U\$C&KX#.(YDZH
M
M
M
M
M
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MF]Q!WLYI'2*B?<MXE5&M3H:VC6IL1$0QP/8/%
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MDC3=QU-S1'1)@
M
M
M
M
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M'[^3%<;N9[O$I5J^65[GO=XW.55HG0FY$V(B(>.'H'F@
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MIN-96O(;S#W;%5B^4QU*\$C'(CXWHBU5CVM=3;2BH9E'.G2@
M
M
M
M
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M9E2+"\WNHUK5=2WN7;$]P>Y:LD<NZ"1RN6J)&^5:HDV(K<6@
M
M
M
M
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M.8]CDJUS7-54<U46J*BT5#[0^8^H
M
M
M
M
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M
M
M
M
M                                                   !\;(LBH<1
MQ^[RO*;BNQ_&L:J;&^R"^MY;,"JIJ6HB.S[.TLITA;<>)!@0F%NNN+424(29
MF?0A]%G:76(7<5C8QOEO9I&LC8Q%<Y[WJC6M:U-JN<JHB(FU54^:]O+3#K.7
M$+^1D-C!&Z221ZHUC&,17.>YR[$:UJ*JJNQ$2I2#\UGS6<AYDY#-T_I^;:8W
MQCQNT(TI,I%=;[AMZZ02HV3Y/&434B)BT20T3M34ND2B429<M/K/@LPM+-"]
M"[33RT;F#,#639TF9X',M&.3;'&NU%E5%I+*GACC7@XG29:\P',!>:E7CLMY
M;=)!D6"3PM?>/:NR65-BI$BI6*)?!)(G'PMBA4%CRL(      'T*JIM;VPB5
M%)6V%Q;3W28@UE5#DV%A-?,C43,2%$;>DR732DS[4),^A#\IYX+6%UQ<O9'
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M8-FS!H,P9?G9<X3<LXF/;]A6N1=K7M6K7L<B.8Y%:Y$5%0R0/'/;
M
M
M
M
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MRQ!\6R[A]G8PTHJ00QQ5_?*QJ*Y>E5<JJJ[555,H#Q#W@
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M -]IZ0?&?:
M
M
M
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MU$1$1.I$H?0'Y'[
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MR6NF<MT09S&FH
M
M
M
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MFQ%>ZG%([[Y[G.7I4RV/!.A
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MRKFV;L1%5?72P)1KEWOBX'^4YLKBP(*I%OP
M
M
M
M
M                  BBLO*IU?N[?^2\F>9.06&^<VM;)",0UHT]-H=-ZXPR
MI<>3BN&Q:N.\S=9C\DQU$[,DRG8<*TG./OO5R3?<2<ZPZYXWEK*D.3-/(F87
MAK&>ZW"HC[NXF<B=K,KE161<2[&-:CWQ,1K6S>2BE?I] ,"S3F^?/.I4S\6Q
M21_N-LBNCL[:%BKV4*,14?-P)M>YZL9*]7O="G$J+*'CF-X[A]'68QB5!2XM
MC5)%1!IL>QRJ@TE'406NIMPZRIK&(L"!%;-1]K;3:$%U]!"$[R\O,0NGWM_+
M)/>2NXGR2.<][W+O5SG*KG+X555)WLK*RPVUCL<.ABM[&)O"R.-C6,8U-S6L
M:B-:B=2(B'VA\Q]0
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MO%K'<6[T5LEM<QT2:"1KD1R*UVUO$C5=&YCZ(CD-CAQYV@
M
M
M
M
M
M                                     'YVHD5AZ3)9C1V9$U;3DQ]I
MEMMZ6MEI$=E<EU"26^MIAM*$FLS-*"(B]!=!_;I'N:UCG*K&[D5=B56JT3HJ
MNW9TG\-CC:YSVM1'NIQ*B)5:)1*KTT38E>C8?H'\']@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\4DP7)^(_',3BMW3N9\7NHJ1->R-SN*>"-BT?(Q.%'*Y>*J)1%5-TA'))P
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M7:Y*THE5V&^(BXED
M                                              Q7NS=FL>.NL<FW
M'N/)ON/UOA_R-]T>1_(V09!\G?=!D%5BU1_Y1BU5=WTOUN^NXK'\!%=\/Q>]
M?:VE:T^YEO+>-9NQJ'+V7H?C&,7''V<?'''Q=G&Z5_ERN8Q*,8YWE.2M*)55
M1%\#-&:,"R9@4^9<RS_%L$MN#M)."23A[21D3/(B8^1:R/:WR6K2M5HU%5-
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M$KCN4KKXWA23.B5_9RQ>Z,1JN;PS1QOV(YNWAHM=BK13.8Y@ZL
M
M
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MN;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                          I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD
M9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^<1
MEC.53OJP[Y/=^;2%\49=FLH
M                                                    !%?YUWV9
M/)?^IK_,!JD3CRW=]&#?WOS&Z(#YG^XS'/[G_P PM"@>-4C(H      #IA<4
M?9;XU_0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J
M/I^U[^+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&
MV_T_;"_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
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M5K&YR4KLJ>Z'F'J@
M        !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\ "0%5.<3NEC]+V_P=P4C1
MI09<@            !T+O*DW@K?? KC_ )1-E%)R#%<6/5F4=5&N0BVUE)=Q
M*(_,7TZ.3+?'*Z!8+5Z>IS/3\;J0R8UURTF5M4L6LHV\-I//\9CZN&Y1)51/
M R1SXT_>&QG+_FE<VZ28/?RNXKRWM_BLO7QVRK"BN\+XVQR+^_ZR1(1&3*
M           %*WWA#?'\X7+K%],5TUUZET#@$&+8Q3<[H[.=;(1"RV\>92DS
M1\?$DX^VL_WQ.-+2?P=!H]RG97_1.0)\Q3-1+G%;MRM7I6"WK$Q%_P#-[=4\
M"HIF+SAYL_3.HL&687*MKA%FU')T)/<\,SU3_P GXNB]-45"!$6E*D
M      3\>[F^VWM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y3
M3<                                 *6_O&7MMZM_17PCZV]X#1KE"[
MM;[TY-YK9&9'.AWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[
MGL0_#VOG$98SE4[ZL.^3W?FTA?%&79K*
M
M  17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\ ,+0H'C5(R*
M     Z87%'V6^-?T Z<^KO'!C-GK_&^,^E;OSB0W"T^_P%@GHBS\WC,_#E3K
MR#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M "[E[O=[!MO]/VPOQ;P$9K\V7>C'Z*@^$G-1N3ONED]+W'P=N3G"LA:L
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MQ0S)'*M.FC51.O:AN"(^)'
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M;_6WH\56YO>[6Q].0^:WI;KDO[T;_P! 3^=V)=(&<IIN
M                 %+?WC+VV]6_HKX1];>\!HURA=VM]Z<F\ULC,CG0[T;#
MT!!YW?$ XM25%     )>_(O^T?U%]ZNV?JVR00!S.=SV(?A[7SB,L9RJ=]6'
M?)[OS:0OBC+LUE
M                                            (K_.N^S)Y+_U-?Y@
M-4B<>6[OHP;^]^8W1 ?,_P!QF.?W/_F%H4#QJD9%       =,+BC[+?&OZ =
M.?5WC@QFSU_C?&?2MWYQ(;A:??X"P3T19^;QF?ARIUY!C[PC[!M1]/VO?Q;S
MX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER      !=R]WN]@VW^G[87XM
MX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M                            :]<D>5&B.).$1M@[\SN-A&/6-BJFI?\
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M$W<NV:5RIJ[A-R]W#9WDJV<O0BMN4[-E5Z$;-V3U5=B<)T%QD^;!@
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MM+]%?-_K;T>*K<WO=K8^G(?-;TMUR7]Z-_Z G\[L2Z0,Y33<
M                     *6_O&7MMZM_17PCZV]X#1KE"[M;[TY-YK9&9'.A
MWHV'H"#SN^(!Q:DJ*     2]^1?]H_J+[U=L_5MD@@#F<[GL0_#VOG$98SE4
M[ZL.^3W?FTA?%&79K*
M                                                17^==]F3R7_J
M:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H      #IA<4?9;XU_
M0#ISZN\<&,V>O\;XSZ5N_.)#<+3[_ 6">B+/S>,S\.5.O(,?>$?8-J/I^U[^
M+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*1HTH,N0      +N7N]WL&V_T_;"
M_%O 1FOS9=Z,?HJ#X2<U&Y.^Z63TO<?!VY.<*R%JP
M                              "II[R;LI4K.>,6GH\HDHH\4SK95M!0
M9]SZLJMZK%\>E/I-/0BBEAMFAHTF77QG.XCZ)Z7PY.<&1F&8UF%[=LL\-NUW
M5V3'22(GC[:-5\24Z3/?G:QM9,5P++;';(K>>Y>WK[5[(HU7Q=C*B>-U>@K%
M"Z918                                             WWXT^9IS/X
MJKKX6N-Q75SAL#PFRUML93N=X&J&T:5%7P:RXD*L<8BK4@NXZ676.GZ2[^BE
M$<69RT8TZSRCY,8P^./$7U_VBWI!/5?9.<Q.&1?PS)$\&Q"6\D:Y:F9 5D6"
MXE++AC*)\6N:SP<*>Q:UZ\42?@7Q+X=JEA_B[[PSH[/#K\<Y08):Z3R!SL8=
MSC%"L,WUM*=-:$G)F5L>,O-L70LW.B6D,7+:4H-:Y*>I)*I.=N4O,V%\=YDF
MZCQ*T3:D,O##<(G4CE7L9/&KH5VT1B[RY.0^<?*N+<%EGNTDPN\78L\7%/;*
MO6YJ)V\6_<C9D2BJKTW$]VM]I:VW#BT+-]4YYB6Q<1L/BQ<APV^K<AJU/$A"
MW8CTJLD2$1;",3A$]&=['V%_%<0E1&0JSC&!XQEZ^=AN.VMQ9W[-\<S'1NIT
M*B.1*M7H<E6N3:BJA;?!,>P3,E@W%,OW=O>X<_=)#(V1E>E%5JK1R>R:M'-7
M8J(I[P>6>L                                    !!C[PC[!M1]/VO
M?Q;SX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER     ;I^7)[>7$7Z?M;
M?C)"$<ZO]UV/^BKCX-23M%^]K+OI>V^$:9-\VC1): YZ;VQZ%".'C><7R-NX
MF265,1G*K92%9#9M06C2EM$&IRYZSKVDHZH2F)VETZ=I>+H-FC]J]+<+NY'<
M5Y;1?%9=M5XK?W-JN^^=$D;UKM\NOA/<YA<I_LAJUBUG$WALKJ;XW%LHG!<^
MZ.1J?<LF66-*;$X*> C?$P$*@  !^ZML9U/8U]O5RG8-G538MC736%=K\2=!
M?;DQ)3*NA]KL>0TE:3_<,A^<T,5Q"^WG:CH7M5KD7<K7)147P*BT/U@FEMIF
M7$#E;/&Y'-<F]'-6J*GA14JATRN.>VZ_?6A=/;FK5LFQLO7.)Y=(9CJ[FX%K
M;TT61=U*C(B(GJ:Y-^(X1>@G&5$77H,8\WX!+E;-.(9=FKQ65Y+$BK[)K'JC
M'>)[.%R>!4-QLEYBAS;E+#<S04X+ZRBF5$]B][$5[/&Q_$Q?"U3- YPZ8
M       J ^\9[W^Z3=6FN/-7,=57ZQPV?GV41VE](J\IV%*;AU$64UUZKFTN
M,XXE]M73M2U<&1&9J41: \H65_B>6\1S;.U.UO;AL$:KO[*!*O5%ZGR2<*^&
M+P(9R<Z&;/CN9\,R; Y>QL;9UQ*B;NUN%HQ%3[ID4:.1>A)EIO4K>BX12D
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MQ[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I SE--P
M                            I;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWF
MMD9D<Z'>C8>@(/.[X@'%J2HH    !+WY%_VC^HOO5VS]6V2" .9SN>Q#\/:^
M<1EC.53OJP[Y/=^;2%\49=FLH
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M;"<-/-/, TRP!<N9<6X=A[KA\RK,]KW\;VL:NUK&)2C$HE.O:;/CBCNP
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MFTC?%<MYBP)RMQNPO;-R+14G@EB5%W47M&MVUV4,<#V#Q0
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MS?ZV]'BJW-[W:V/IR'S6]+=<E_>C?^@)_.[$ND#.4TW
M                "EO[QE[;>K?T5\(^MO> T:Y0N[6^].3>:V1F1SH=Z-AZ
M @\[OB <6I*B@    $O?D7_:/ZB^]7;/U;9(( YG.Y[$/P]KYQ&6,Y5.^K#O
MD]WYM(7Q1EV:R@
M                                           $5_G7?9D\E_ZFO\P&
MJ1./+=WT8-_>_,;H@/F?[C,<_N?_ #"T*!XU2,B@      .F%Q1]EOC7] .G
M/J[QP8S9Z_QOC/I6[\XD-PM/O\!8)Z(L_-XS/PY4Z\
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M45*HI=S"L6PO';"/%<&N(;K#9DJR6)[9&.3=L<U51:+L5*U145%HJ'K1\!Z
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M][M;'TY#YK>ENN2_O1O_ $!/YW8ET@9RFFX
M        4M_>,O;;U;^BOA'UM[P&C7*%W:WWIR;S6R,R.=#O1L/0$'G=\0#B
MU)44     E[\B_[1_47WJ[9^K;)! ',YW/8A^'M?.(RQG*IWU8=\GN_-I"^*
M,NS64
M                                   BO\Z[[,GDO_4U_F U2)QY;N^C
M!O[WYC=$!\S_ '&8Y_<_^86A0/&J1D4      !TPN*/LM\:_H!TY]7>.#&;/
M7^-\9]*W?G$AN%I]_@+!/1%GYO&9^'*G7@
M
M        &!-R\6>.7(2,Y'W5I37&QG5M(91;9'B]:_D<1IM/8A-;E+++&25?
M:CXI'&EM'V^CX!U.7<\9ORF]'Y;Q*\LVUKPQR.2-5^^B55C=_":IR.9<A9+S
MBQ69GPNRO7*E..2)JR(GWLJ(DC/X+T(:=]^[O\9,V;EV.A-A9WH^Z63ZXU+<
M+_G.P4E>ER/&;C7,RLS2&2E'X:GW+F;V(Z*)I:DF2[$Y6YM\Z8:K8<TVEKB=
MMLJ]G^S3>%:L1T*]:-2%E5V<2(NRM.;>3;(V*-=-E*\N\*NMM&/_ -J@\"4>
MYLR=2N69]$HO"JHM8/\ D-Y)_.[0Z)UK4X!!WGB<0UJ*\TM-D9-:DQV*=:\?
M YL.JSI<DVD&3B8<"<RVX7;XRNJ#79;*7,CI?FA6P3W;L,OW>PO$2-M=VR=J
MN@I7=QO8JIMX4VTJUG'E?U8RFC[BWLV8KA[?YRR<LKZ;TK YK)ZTW\$;VHNS
MB6J*L4%K4VM%93:>[K;"FMZV0Y$L:JUAR:^R@2FC[78TV#+;9DQ9#:O0I"TI
M41_"0G:">"ZA;<6SV26[TJUS51S7(NY4<E45%ZT4K[<6]Q:3.MKICXKABT<Q
M[5:YJIO1S51%14ZE2I\\?J?B                  &V'%7FSR-X:94>2Z-S
MR53P)DIF3D>"7*7+G7N8):)I"F\BQ=U]EAR0XPT313HJXEFRUU2S):ZF.$SS
MIME#42Q^)9FM6R2M:J1SL\B>*M?Y.5$5:56O Y'1JNUS'$@Y U0SIIIB'Q[*
MMVZ.%SD62!]7V\U*;)(E5$K1*<;%9*U-C7M+@O [SE>/G+MRFU_G1QM';VG&
MS"CXED-FVYB&9V"B)"4X%ETE,5EZ=+<Z>'53DQYQK63<<YG:IP9^:H\N^;,@
M))BN%\6)Y7;55EC;[K"W^OB2JHU.F5G$RB5?V=40T>TFYELGZBNBP?%N'"LU
MOHU(9'>XS._J)EHBN5=T4B-DJO"SM**I,6*]%D@
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M);@;5I]2TTA;BOD/4V(4U&EHE=2;2SD=^WD^;M>"A1D79:))77JHC,DF5B\
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M1J5DK42S6[RE?PW+FMJ^+:R>/H]TA?21J5V(_A5CE]:YQLX.*.Z
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MYC6H?9XYCBR6&4%6J/HG;7*(M%2!';&LWHLSD5M=C&OV\-9-:N9' M-NTP#
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MJ9FYFS7F+.6*OQO,]W->8E)O?(M4:E57@8U*,C8BJO"R-K6-KL:AB<>Z<\
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MBIL5%1=J*B[%1=Q>V.2.:-LL3D=$Y$5%145%14JBHJ;%14VHJ;%0_0/X/[
MH=>>A]H_MW[U=3?5MC8U$Y8^Y[#_ ,/=><2&37-7WU8C\GM/-HR(03^5S
M  )^/=S?;;VE^BOF_P!;>CQ5;F][M;'TY#YK>ENN2_O1O_0$_G=B72!G*:;@
M       !ROQN&8'       7<O=[O8-M_I^V%^+> C-?FR[T8_14'PDYJ-R=]
MTLGI>X^#MR<X5D+5D5_G7?9D\E_ZFO\ ,!JD3CRW=]&#?WOS&Z(#YG^XS'/[
MG_S"T*!XU2,B@      .F%Q1]EOC7] .G/J[QP8S9Z_QOC/I6[\XD-PM/O\
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M%V0
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M$7Z?M;?C)"$<ZO\ ==C_ **N/@U).T7[VLN^E[;X1IT;1D$;1D6WG)Z)/>O
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MPS5K+'Q]J,@S%:\++NW1?6/5%X98T55<L,M%5BK56N1\:JY6<3I#A$A,@
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M3SS7,S[FY>Z2XD<KG.<JN<YSEJYSG+55<JJJJJJJJJU4_"/T/R
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M)?WHW_H"?SNQ+I SE--P        Y7XW#,#@      +N7N]WL&V_T_;"_%O
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M96%-B[H
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MG2B%=\>RYCV5[]V%YBL[BRQ!J5[.:-T;E3H<G$B<35Z'-JU>A5,<CUSQ0
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M5.O- _-,^SVY7?17/^<ZL2KH?WLX%\N;[5Q$6O?<[F#T>[VS3G=C6XQK
M   Z(GE9_9[<4?HK@?.=H,D=<.]G'?ESO:M-E-!.YW+_ */;[9QOX(J)=*FO
MO*O\=^)7WJ[=^=\ %\.3?]68]^'M?:3F>_.[^M,O?)[SV]N5B1=,HL
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MQH2S;W%O=PMN;5[);=Z5:YCD<UR=:.1514\**?0'Y'[
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MUS;7MM'>6<C);25B/8]CD<Q[')5KFN:JM<UR*BHY%5%1:HM#Z0_$_<
M            (,?>$?8-J/I^U[^+>?"S?*;WHR>BI_A("JG.)W2Q^E[?X.X*
M1HTH,N0    #=/RY/;RXB_3]K;\9(0CG5_NNQ_T5<?!J2=HOWM9=]+VWPC3H
MVC((VC  I9^\*:(+7_+3$-T5L$H]+OO7\5RQE(;4E,K.]:^IXQ>=3(S;ZEB,
MK'S]'0U+4HS+KZ3T;Y3,T?I;(5QER9U;G"KM>%.J"XK(S_U4G]2AF/SBY3_0
M^H=MF>!E+7%[-.)>N>VI$_P?R*V_JU\9 6+4%1@   _5"FRZZ9$L($E^'.@2
M6)L*9&<6S)B2XKJ'XTF.\V:5M/L/(2I"DF1I41&0_B2..:-T4J(Z)S5147:B
MHJ45%3I14V*?I%+)#(V:%RME8Y'-5%HJ*BU147H5%VHITP.,&XX?(/COI;=<
M1<=2MDZXQ;)[-F+T\&!D,RK83E%0GI\4ETN1M2HB^GH);)]/0,9\ZY>DRGF[
M$LMR5I9WDL;57>Z-'+V;_P"'&K7)X%-P<B9ECSCDW#,SQJE;VRBE<B;FR.8G
M:L_@2(]B^%IG8<N=8   % 7SCM\?S[\^MQ/PIKLO&]42(>DL;2XYWHCHU\<F
M-E:&.AFV4=[8<VY=;-/H4VXD_A,:K<O.5_V7TKPYLC4;>7Z+>2>'MZ+%7PI;
MI"B]2HID/S)YL_:S5W$G1.5UEAZMLH_!\7JDM/ MPZ94ZT5%(N1-I P   24
M^4?H1'(+GII*BL(/KV+Z_M7]Q9<E2#=815ZX2U<4S<MG]X]"L\W54P7D+/L4
MW*,E$HOBJAS7S-*Y3TMQ*ZB=PWMVQ+2+KXKBK'T7H5L/:O14VHK=E-Z3=R[Y
M23.&K6%VDS..PLY%O)NE.&VH]B*G2UT_9,5%V*CUK7<O07&3YL& !4U]Y5_C
MOQ*^]7;OSO@ OAR;_JS'OP]K[2<SWYW?UIE[Y/>>WMRL2+IE%@    "?CW<W
MVV]I?HKYO];>CQ5;F][M;'TY#YK>ENN2_O1O_0$_G=B72!G*:;@ 4Z/> ^9#
M^QMPT/$O#+@W,(TR<;(]C(AO$J+=;7N*]2H-=(4@UHD-X+B]@2$]JB[)UG+:
M=3WQT&G0KE2T\;A&7I<^XC'3$L1K';U3:RU8[RG)U=M(VOA9'&YJT>M<VN;[
M4IV-9DAT\PR2N%X922YHNQ]V]ODM7K[")U-^Q\LC7)5B4KK"W)3,     ]UK
M+6N;;BS_ !+5^N*";E&<9Q=1*#'*. CO?F3Y:C^,XL^C<6%#80M^3(<-+,:,
MTMUQ26T*47F8UC.&Y>PJXQO&)6P89;1J^1[MR-3_ $JJT:UJ;7.5&HBJJ(>M
M@>"8IF3%[? <%A=/BMU*D<;&[W.7]Q&HE7.<M$:U%<Y41%4O=>79Y7&G>$&(
MU&06]92;"Y&6,!+F6;2F0BEMT$F2T92<<UJU8->+CU##0ZIER8A#-A:?&<D&
MAI346/E]JYK=F'4O$)+2W?+:908[W*V1:<:(NR2X5JTD>N]&*JQQ;$95R.>_
M6#1G0;+>EF'1WERR*\SH]E9;IS:I&JIMCMD<E8XTKPJ]$227:KZ-5L;)3!"!
M/8   :@\P.#^@N:^ R</V_BL8[Z)#?;PW95/'BQ<^P6:LG5,OTET;1NR*LY#
MIKD5DGQ:^6?0W&O$2VXW(&GVI>:M-\53$,OSN^*N<G;6[U58)DV51[*T1U$H
MV1M)&]#J*J+'.H^EF4=4,(=AN8[=OQMK52&Y8B)<0.VT5CZ55M5JZ)U8W[U;
MQ(UR4&^7G%#9G#/=V2:5V;'0]+K>RSQ?*(;#K-)G.'3GGT4N5TGBJ<-,>:4=
M;3[!K6N'-9>CK4I31F>IV0,]X+J)EJ',F"K2-_DRQJJ*^&5J)QQ/ITI5%:ZB
M(]BM>B(CC([4;3['--,TSY8QUM9&>5%*U%1D\+E7@E97H=14<VJJQZ.8JJK:
MFL([4X4     DW\ISF1*X>\L,5LKJR.-J;:[]=K;:\=]_P .OA55K8M(H<T>
M)9^$V_A%T^F2M[M-PJYR8TCH;QB%]=]/&:@Y$GAMF<6/6".N+543RE<UJ\<*
M=-)F)PHF[M$C<OK2<^7S4J33?4&WGN7\.7L05MM=HJT:UCW)V<R]"+ ]>)5W
M]FLK4]<= D92&OP %+?WC+VV]6_HKX1];>\!HURA=VM]Z<F\ULC,CG0[T;#T
M!!YW?$ XM25%     )>_(O\ M']1?>KMGZMLD$ <SG<]B'X>U\XC+&<JG?5A
MWR>[\VD+XHR[-90 * /FY<OI'+;E[F,FDM')FJM0OSM7:OCM2#<K9<.DG.-9
M1F,9"%>KNN9GDC+K[4@DI=<JV8+;G4V4]-5] ]/V9"R!;LN6(W'<01MS<JJ>
M4BO;6*)>E.QC5&JVJHDBRJGKC(7F)U&?J'J-<OM9%=E_#E=:VJ(M6JC'*DLR
M="]M(BN1U$58DB:OK4(O1-A!     !9V\D_RML3V)0U7,7D7C<?(L?=LI:=(
MZVOH3<BCN/DB4N'+V1E-9*0MFVKV[1AV/40GT^ XN.Y+<0X@XBA2SF1UNO\
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M^0L6TVS==94Q;RY(51T<J(J-FA?MCE:FVG$FQS:KP2->SB56JIK(.T.&
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M1S=:AOS#G6/)5A)7!\';[HB>M?>2)5ZK38O91JV)*[6/69.E2 D6H*B@
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M,!Q_&<L8K%C> W$EMBD#JL>Q=OA146J.:Y-CF.16N38Y%38>+F'+N"9KPB;
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M\YU8E70_O9P+Y<WVKB(M>^YW,'H]WMFG.[&MQC6      !T1/*S^SVXH_17
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M27,;$LEDFRG?<3K65VUS%:OEV\BIO?&BHK741)&*CD3B1Z-BZ$VD#@
M7O?(NV8YL/R\]>U,F24N;JC,]@ZSE/&[XCQ-Q[O[MJF-(+O5X1P:#.(C#2>B
M>D=ML^A]>X\ON9S!4PG5J[N&)PQW]M!<HE-FUG8O5.OBDA>Y5V^4J^)-8N5/
M''8SHY9V[W<4N'W-Q;*M:K1']NQ%ZN&.=C439Y*)XUF#%?2QX
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M\TNG46<].Y<=M&(N.X(CKABHFUUO1/C,:^#@1)DV5XHD1*(YQ1:&G)E,
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MR'>XR\)-W;"JIZZ[+[:@3KS GV'/"FM9=G[Q8Y$L:]?>CMFXY6RY=LD^OH*
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MGR.5SE]5553<;"L,LL%PRWP?#6)%A]K R*)B;FQQM1C&^HU$0]2/A/O
M*W7O&6A(5_IC3O(ZM@-_=!KO,W=;9++8824B3AN<PIEI4/6$G]\J'C^4T7A1
MT'^]=NW3+]\8N'RA9JEM,QXAD^9R_%+NV2XC15V)-"J->C4ZY(GU<O5"WJ*4
M<Z&48KS+.&YU@8GQRRN5MI51-JPSM5[%<O5'+'1J=<[NLJ"#0 SE     )"_
M*NWL[Q]YVZ"RQZ647'\IRMG5F7DZM2(J\>V7TQ4Y$U2#)11J2ZGP[/K\!+@I
M,R-/4CB;7'*[<V:7XK8-;Q7<$"W,5-_:6_NM$\+V-?'XGJ3'H'FQV3]6,(Q!
MSN&SN+A+6:N[L[GW*KO Q[F2^-B=!T-1DJ;'&)-][:I]#Z4VKN:^)MRLUE@.
M49F[%<<\'Y2D453*FU].TY^Y)NK!MJ(R7PFZ\DOW1[V5L!N,T9DL<NVM4GO;
MJ.%%I7A1[D1SU\#&U<O@13GLVYAMLIY7Q#,UW18+&TEF5%6G$L;%<UB>%[D1
MB>%R',^S'++[/<NRK.LJG.6F3YID=YEF1V;O_BV-]D=G*N+B<[U,S\2783''
M%>GX5#9G#["UPJP@PRQ:C+*VA9%&U-S61M1C&IXFHB&'F)8A=XOB-QBM^]9+
MZZG?+(Y=[I)'*][E\;G*IYL?8?$     7I/(FT1'U)P5QS.)<-#&3[[R>_V/
M:/+093$X_"F.XCAD!;G0B7".IHEV3!%UZ?*BSZ]3,BS&YG\T/Q_4Z;#(W5LL
M*@9;M3H[14269WCXGI&[\$AJSRH939EW2F'%9&TO\7GDN7+T]FU5AA;^]X(U
MD;^%7K)G!74LP   $%OG_P"B(6Q^%\;;T:"VO)>/V<45VB>E*52DX;GMA7X/
MDM:V78IQ;#]W84TQWH9=B(!J/XI*,6<Y4\T2X/J,[ 'N5+/%K9[.'H[:!KIH
MW+X48V9B=:OIOH53YO<IQ8UIDW,;&(M]@]U&_BZ>QN'-@E:G@5[H7KU)'7=4
MI(C2<RZ     /UP)TRKG0[*ODNPY]=+CSH,MA9MOQ9D1Y$B-)967I0ZP\VE2
M3_<,A_$L4<T3H941T3VJUR+N5%2BHO@5-A^D4LD$K9X7*V9CD<U4WHJ+5%3P
MHNU#IZZFS=O9FJ]9['90VVUL#7^&9NTVRKO:;;RO'*V^0AI9D7<VA,\B2?3T
MD,5<>PU<%QR]P=RJKK2[FA6N_P!RD<S;_%-U<O8HW', L<::B(V\LX9T1-U)
M8VR;/XQ1Z\]#[1_;OWJZF^K;&QI=RQ]SV'_A[KSB0RRYJ^^K$?D]IYM&1""?
MRN8    !/Q[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?WHW_H"?SNQ+I S
ME--P        Y7XW#,#@      +N7N]WL&V_T_;"_%O 1FOS9=Z,?HJ#X2<U
M&Y.^Z63TO<?!VY.<*R%JR*_SKOLR>2_]37^8#5(G'EN[Z,&_O?F-T0'S/]QF
M.?W/_F%H4#QJD9%       =,+BC[+?&OZ =.?5WC@QFSU_C?&?2MWYQ(;A:?
M?X"P3T19^;QF?ARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW
M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
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M4J.3X9>GI7U=%^2:_=)E?',+55X(;^&5$Z*S0JQ?L]@E=G0F_HLFBG)=H
M               *>GO(&NU5'(C06TD,^%&SO4-MABW$H)*)-EK?+I=K*=4H
MB(W)"8&R(C:C,S,FT(+X"&@W)]BZ7&4L5P-5J^UQ!DWB;<1(U$\7%;O7QJIF
M_P ZN#+;9RPC'T2C+O#GP^-UM,KU7Q\-RQ/$B%<H6]*7            >GQ#
M-<RU]?0\JP++<FPC)ZXS57Y'B%]:XU?05*Z&I4.XII4*PBF9I+J:'$_ /BQ#
M#<.Q:U=8XK;PW-D_UT<K&R,=XV/16KZJ'W8=BF)8/=MO\(N)[6^9ZV2&1\4C
M?WKV*UR>HI,YQL\^OF)IQ<"GVTC'N1V'1C:;=;RY",8V S$0LU*:@9[00E-R
M'G$K/N>MJRV>/HDB6DBZ'77.7*UI[F%'W& ]K@^(K6G9>Z0*O6Z![MB>"*2)
M-^Q2S.2>;;4C+2LMLP]CC6&MHB]M[E<(G4VXC;15\,L4J[MJ%AGC#YSO";D@
MJOI+#-G]&Y]-.+&3B6XC@X_ F3WS\(V*/.&)4K#[!M4DTML)DRH,V0:T]L8C
M,TIJ5G7ETU)R>C[F*V3$\*;5>UM.*1R-3I?"J)*W9M<K6O8VBU?TK<?(G,SI
M?G566LUTN%8NZB=C><,;7.792.=%6%VW8U'.C>ZJ4978DL#3K4AII]AUMYAY
MM#K+S2TN-.M.));;K3B#4AQMQ"B-*B,R,CZD()<US'*UR*CD6BHN]%ZE+!-<
MU[4>Q45JI5%3:BHO2A_0?X?Z                            'FLQPW$]
MA8O>83G6-TN7XADM>]59!C615T6VI;BO?Z>+$L*^:T]&DM&I)*+N29I6DE%T
M41&7V8?B-_A-[%B6%S26^(0O1T<D;E8]CDW*UR*BHO\ ]-FX^'$L-P_&+"7"
M\5@BN<.G8K)(I&H]CVKO1S7(J*G^A=J;2I=YCGD7Y%K=-[N7AC M\SP-KUJT
MR/23CSUMFF(QR-;[\C I+IKGYG016^I% =4[<,)278N;W*-J^>D',Y:8PL67
M=17QVV*+1L=Y1&PRKN1)T3R87K]VE(G=*1T3BSUUIY4[S!$ES+IFR2YPE*ND
MLE57S0IO5;=5\J:-/Z-:S-3<LM5X:W+K3L=UUA]IQE]EQ;3S+J%-NM.MJ-#C
M3K:R2MMQM:3)23(C(RZ&+AM<U[4<U45JI5%3<J=:%*'-<QRL>BHY%HJ+L5%3
MH4_F/]/Y             "8KRLO--RKA+E4?6NRI%KE7&/*K7Q+BG;\6?:ZO
MM9[I%)S/#(QFIQV ZXKQ+6J;Z)E)(WV"*42DR*]ZX:'V.I-BN,X,D<&=((_(
M?L:VY:U-D,R]#DW12KZWUKO(HK+):":]XAI?B#<$QMTEQD6XDJ]B5<^U>Y=L
MT*=+5WRQ)Z_U[/=*H^\CAV8XKL+%<?SC!\@JLJQ#*JJ'=X[D5),:GU5Q53VD
MO1)L*6RI3;K3K:O^Y25$:5$2B,BS,Q'#K[";Z7#,3BD@Q""1621O16N8YJT5
M%1=RI_\ =-AJCAN)8?C&'PXKA4T=QAUQ&CXY&*CF/8Y*HYJIO1?W-R[3TH^,
M^X               @Q]X1]@VH^G[7OXMY\+-\IO>C)Z*G^$@*J<XG=+'Z7M
M_@[@I&C2@RY     -T_+D]O+B+]/VMOQDA".=7^Z['_15Q\&I)VB_>UEWTO;
M?"-.C:,@C:, #P>T]>46W-9[!U9E#?B8[L?"\GP>[(FTN+369333*68ZRE1I
M+UAAF::VSZD:7$D9&1D1CU,#Q:ZP#&K3'+):7EG<QS,_?1/1Z(O@54HO@/)Q
M_!K3,6!WF 7Z5LKVUE@?T^3*QS%5/"B.JGAH<R?/,,N]<YSF>O<F8*+DF!Y7
MD6&9!&29FF/=XO;S*.V82:DI49,SX+B2ZD1^CX!M#A>(VV,89;8M9+Q6=U!'
M-&O6R1B/:OJM<AAIBV&76"XK<X-?)PWMI<20R)U/B>K'IZCFJ>3'W'G@  !.
M=[O]NS^;GFM,UC/F>#3;XUW?XTS'<<\*.O+\-;/.,>DN*4M+9NIIJJWBM$9&
MI;DTDI]*NAUDYK,M_I?3=N-1-K<87=QR*N]>RF]QD3Q<;HG+U(RJ[BU?*#FC
M]"ZGNP*5U+;%K*2)$K1.VA]WC5>BO R9J=:OHFU2[D,US48 "O[[PWOC[@^*
M^":/KIKK%QO?/VY5K':<[42<%U>4'(+5F0E)]WQ\RLZ!;9'\51,K^$TBUO*5
ME?\ 2F>+K,TS46WPNTHU5Z)[GBC:J?\ DMG1>JJ=94'G'S9^B<@VF5H7*ESB
MUY5Z)TP6O#(]%_\ .=;JG0M%ZBF"-%C,P   /]MMK=6AII"W'7%I;;;;2:UN
M+69)0A"$D:E+4H^A$7I,Q_BJC45SEHB'^HBN5&M2KE.D;P8T*7&7B1H?2KT?
MU6YQ+ ZZ1EK7Q5&G.<G=D99G*2<3_P"(TUEEY,0T9F9^"E!?N#'C4W-/[:9]
MQ3,C5XK>XNG)$O\ 4QHD4/JK$QBKX54VOTJRE^PVG>$Y8<WAN;>T:LR?U\JK
M+/XT25[T3P(AM@.$)!  J:^\J_QWXE?>KMWYWP 7PY-_U9CWX>U]I.9[\[OZ
MTR]\GO/;VY6)%TRBP    !/Q[N;[;>TOT5\W^MO1XJMS>]VMCZ<A\UO2W7)?
MWHW_ * G\[L2Z0,Y33<@@]X.W*Y@7#&@U?735,6>\=H45/814K\-4G#,'8?S
M.Z<(RZK63.40J)"DD1$I#Q]3]':JT/*=EU,4U%EQN9M8<,LGO:O5-,J0L^S&
MLZUZT]5*G<X69781IG#@,+J3XK?QL<G7# BS/^Q*V!*=3M_0M)X:1&7X
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M3IE]3[%0><O %Q#3RRQZ)M9<.Q%J.7[F*X8YCE]65L">KOZZ8(T6,S
M           -ZN*_F/\ +CA_(A1=5;/L)V#QY#;TG5F<^-EFNY;2"Z+CQJ:;
M(1,QKU@B+Q'J:36R'.Q)*<422(1CGG1_(.H#'28Y9,;B:HJ)<PTBN$7K5Z)2
M2G0DS9&I5:(E25\@ZU:B:</;'@%^]^%-5%6UGK+;JG4C'+6*O2L+HW+1*JJ(
M6=>(7GU<:]VJK<2Y P3XX; DFU&3<6LY=SJ.XE*,D$XUF!1X\S$#>-*G%HN(
M[4&,CHD[!U0I9J!RMYRRTC[_ "H[],82E5X&MX+IB>&*JI+3<BQ.5[EV]DU"
M]&G/-KDC-"LP[.#/T+C#J)QO=QVCU\$U$6&N]4F:C&IL[9RDZ-5;55[60+JC
MLJ^YI[2*Q.K+:JF1K&LL8,EM+L:9 GQ''HLR+(:42D.-K4A:3(R,R%8IX)[6
M9UM<L?'<,<K7-<BM<UR;%1S5HJ*B[T5*H6LM[BWNX&75J]DMM(U'->QR.:YJ
M[4<UR*J*BIM146BGT!^1^P                            0?>95Y-^NN
M6+-YM_1K=+J_D634B?8-(81 P;;<DB-U3.6,14=E%ELE?7P[MAM1R%J-$YMX
ME(D1K+Z-\PV+Y#=%E_,RR7N4*HUJUXIK5-U8E7U\2=,+E\E-L2MHK'U9UNY:
M\%U";+F/*J16&<Z*YR4X8+M=])43^3E7HG:B\2[)4=5'LI>;,UCL#3><9#K;
M:.)7.$9SBTYRNO<<O8WJTV'(;/XKC:DJ<C3H,IOHY'E1W'8TIE2767%MJ2H]
M&,&QK"<Q89%C&"3QW.&3MXF2,6J*G^EKDW.:Y$<U:M<B*BH9E8Y@6,9:Q6;!
M,>MY;7%;=ZMDCD2CD7_0YJ[VN:JM<U4<U5144\&/4/)             ":;R
MF/-&M^&F7QM0[9FSKGC1G%XQZXXX[,FR]/7EB^33^98_#2;QNXS*<>\2[KF&
MS=<2GUN,2I"'&)E<M>=$;?43#US!@+6QYSMHEIL1$NV-2J0R+LI(E*0R*M$_
MDWT8J.CLYR]:\W.FF(MRYF%SY<CW4J<6U7+9O<M%FC3;6)56L\;4JM.T8BO1
M627AJ2[ILEIJK(L=M:Z]H+VNA6])=U$V/8U5O56,=N77V5;81''HLV#-BO)<
M:=;4I#B%$I)F1D8S0N;:XLKB2TNXWQ743U8]CT5KF.:M'-<U:*CD5%145*HN
MQ34ZUNK:^MH[VRD9+:2L:]CV.1S'L<E6N:Y*HYKD5%14545%JA]0?@?N
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M4VM5-J;=QX69N975#-N 766\8ELG89>1+'(C+=K7*U51=CD78NS>15"<B 0
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M+\6\!&:_-EWHQ^BH/A)S4;D[[I9/2]Q\';DYPK(6K(K_ #KOLR>2_P#4U_F
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M"-     "U![L]_SK?].'_'D4>YS/^F_^(?[B7YY'O^J/^&_[^6H!1TOP
M              &H//S3+G(#AER.U1%CG+ML@UC=V>-PR3WG,R_##8SC#8GP
MEV%*RK&X;9K+J:"5W$E1EVG(&E68DRIJ+@^.O7A@BO6-D7JBFK#,OJ12/6G3
MNJF\CG5W++LX:9XUE^-.*XFL7NC3KFAI/"GJRQL2O1OHNXYOHV#,5
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M;ADS-G]8W@^QY6WP5)3T1MOC6KF78MFS%8'[=WN;NT^SY.SJ6AT81D.;/
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M_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN        '*_&X9@<
M     !=R]WN]@VW^G[87XMX",U^;+O1C]%0?"3FHW)WW2R>E[CX.W)SA60M6
M17^==]F3R7_J:_S :I$X\MW?1@W][\QNB ^9_N,QS^Y_\PM"@>-4C(H
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M_.M_TX?\>11[G,_Z;_XA_N)?GD>_ZH_X;_OY:@%'2_
M  !S?^?>B?\ #9S%Y :@CQ40Z2@S^QML1CM-^&PSA&9-1\SPR,ST-3;GJ.-7
M\6.X:3Z>,RLNB3(TEL'I7FC]L=/<*S ]W%<RVC6RJN]9H56&95_?2,<Y/ J;
M]YBKJ[E/]B=2<8RXQO#:PWCGPHB;$@F1)H43][%(UJTZ47=N33\2 1P
M                !,#P6\Y+D?Q%538/F<F3O/1D,VHA85E=FZ64XE7=4H,\
M S.0W+G068;24^%63BEUGAI-ME$12S>37[4[EXR?GY),3PYK<,S.ZJ]M$U.R
ME=_7PI1KE7ID9PR56KED1.%;':4\RN==.EBPK$W.Q7*C:)V$KE[6%O\ ^/,M
M7-1$W1/XXJ)PM2-5XDN)\4N:?'KF;AAY=H_-XUQ*@,15Y3A%JE%3GN%29*"-
M,;)<:==<D,L&[W-M3HRI-;*<;64>0[V*Z9[YZTXS;IUB/Z/S-;.C8Y5[*9OE
M03(G3'(B45:;58[AD:BIQL;5#2/3_4[)VIF&?I'*MTV21B)VL#_(N(57HEB5
M:HE:HCVJZ-RHO ]U%-K!PI(                           &KG+?B%IOF
M=JBSU9MZB:D)-J5(Q#,8,>,G+M?9 \VV3-_BMF\TMR*[XC#92HQF<:>PCP7T
M+1TZ=OD+/^8M.L=9CF7Y51:HDL+E7LIXTWQRM1=J;5X7>N8J\3513@]1-.<M
M:F9?DP#,<2.2BK#,U$[:WD7=)$Y4V+L3B;ZV1J<+T5"A5S:X1[>X-;:DZWV5
M%^5*&R]:L-=['K83\?&MA8ZPZA'K\ G')'R;=5_C-HLJQQUQ^ \M/QG6'8\A
M_4G3;4K -3<!;C&#.X+IE&W%NY462"14]:[=Q,=15CD1$:]$78U[7L;DIJAI
M=F/2K,+L$QMO:6CZNM[EK52*XC1?7-JJ\+VU1)(E571N5-KF.8]VFXD,C4
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M;S*LTR*N]>%[U8BK[%J)1$1$3<L1V26   %37WE7^._$K[U=N_.^ "^')O\
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ML%MJKE5/CSF,S=8M:R[C2B<?0RY8GW$M/*1$I'(CFT1O KI1!"1/
M  !!C[PC[!M1]/VO?Q;SX6;Y3>]&3T5/\) 54YQ.Z6/TO;_!W!2-&E!ER
M  ;I^7)[>7$7Z?M;?C)"$<ZO]UV/^BKCX-23M%^]K+OI>V^$:=&T9!&T8
M !SZ?-ST2>@N?&\J:'!.%C6PKEG<F)]&TLL/UNRDN7=V4)A!FAB#6YS\KP&4
M)Z(0B(1))*>B2U?T"S1^U6EF&7$CN*\M(UM)>E4=;^0RJ]+G0]D]57:JNVU7
M:8^<Q.4_V1U<Q6VC9PV-Y*EY%T(K;FKW\*=#6S]M&B)L1&;$1-A&J)D(1
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M?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
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M2OB3AJO@J2CHG<_%-6\NRU1*XM;LV[O='I'3QKQ43PT.C,,A3:
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M2/IG"ORNW_M!_E]GWZ$Q?\CN/[,?X4>4GYM>_O['-B?R<#]NLD?3.%?E=O\
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MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\                    &FOF
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M,F!9MP>''LN7,5WA,[:LD8NSPM<BT<Q[5V/8]&O8M4<U%2ADL>,>X
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ME-R_==2^(]_*F*)@>:<-QI5HEGB%O/7J[*9DE=Z?<]:>,Z=@Q8-T@
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M6PI;^\9>VWJW]%?"/K;W@-&N4+NUOO3DWFMD9D<Z'>C8>@(/.[X@'%J2HH
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M)QTK]E43U2S/*5(QFLENURT<^QND3PKV?%3["*OJ%Z09C&K
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M !^';LJJ=-"UG)U.L.K,L:.1O:X/<-IL\JDMN^B?Q.+9MHU>BI=N&;!J*
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MARIUYH'YIGV>W*[Z*Y_SG5B5=#^]G OES?:N(BU[[G<P>CW>V:<[L:W&-8
M    '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?]'M]LXW\$5$NE37
MWE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46     -
M_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M!SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_  :&+FM'>UF+TO<_".-+!(Q&(
M !:@]V>_YUO^G#_CR*/<YG_3?_$/]Q+\\CW_ %1_PW_?RU *.E^
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M+\L:FX3\0QN/@OXT7L+EB)VT+EZE]G&[V<3O)=O3A>C7MD[3#5G->E6,_I'
M9./#Y%3XQ:O5>QG:G6GL)&^PE;Y;=R\3%>QUZSAKS<TAS>UJWGNI;KP;>M1$
MC9UKRX=CLYE@=Q(9)SU.W@MK,Y=5)62RA6;!*AS4MK)"DNMO,M9AZB::YETT
MQE<+QZ.MN^JPW#$589V(N]CNAR;..-WELJE45JM<[5S335'*VJ6")BV7I:7+
M*)/;O5$F@>J;GMZ6+MX)6U8^BT5'-<UNX C\D<
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M)2W]XR]MO5OZ*^$?6WO :-<H7=K?>G)O-;(S(YT.]&P] 0>=WQ .+4E10
M "7OR+_M']1?>KMGZMLD$ <SG<]B'X>U\XC+&<JG?5AWR>[\VD+XHR[-92FS
M[QIK==#RCTYLYF.AF!L33/W/O.)29'+R#7N5W"K&0XO]ZI::/,*MKH7I)+9?
M]HT/Y0L82ZR1B."N6LMIB/:)X(YXF<*?QXI5]4S5YT,$6TSYAN.M2D-[AG9J
MO7);ROXE_B31)ZA7E%M"G     !)GY.V:L8-YCO&JPEOH8A7E[EV%2$K<0RB
M0_FNO,MQFG8-Q33I]ZL@LH:D)223<6E*.XB49B&.83#78GH_C,4:5DBBBF3I
MHD,\4CUWI_-M?7J2JTV$Y<MV)LPK6G YI%I%++-"NVE5GMYHF)N7^<<RB=*H
MB52IT#1E&:_@                 !"=Y^&G'MD\$9V:U\7QK31^Q\0V XMI
MOQ):L=ME3=?WT5LB0M7JB'<OB3I'3IVMP.\S)*%$=D>5C,+<&U0;ALKJ08G9
MRP;=W:-I.Q?'2)S&^%]-ZH5?YN,MNQO2=^*0MK/A5[#<+1*KV;^*WD1/!69D
MCNI(Z[D4HX#3(RN       Z*/EB[*:VOP$XL94B0N4]!U328)/>==4](79ZN
M=E:VL')3CA$ZJ0_*Q13BE+ZJ7WDKJKN[CR,UIP9V!:J8Y8JG"UU^^=J(E$X;
ME$N&TZ*(DM-FZE-E*&S.A>-MS!I%@%^B\3F8>R!RJM5XK55MG*O355B5=N^M
M=M:F]XB\E@   -8.;&;1]<\/^3V:/O&RJCT1M)V"I+I,+<N)>'6]?11T/*;=
M)ER7<RV&DJ[%]JED?:KX#[73;#7XOJ#@F',2J2XI;([97R$F8YZTV5HQ'+2J
M;MYPFJ&*,P73C'<3>M%BPFZ5NVGEK"]L:5VTJ]6I6BTKN4YKPV.,20
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M>V:<[L:W&-8      '1$\K/[/;BC]%<#YSM!DCKAWLX[\N=[5ILIH)W.Y?\
M1[?;.-_!%1+I4U]Y5_COQ*^]7;OSO@ OAR;_ *LQ[\/:^TG,]^=W]:9>^3WG
MM[<K$BZ918     W\\K3[0GBC]*E?\VV8BO6_NFQWY"[VS27=!.^++_I!OM7
M'1$&2!LH        '.2\QOV\N77T_;)_&2:-?=(.Z[ /15O\&ABYK1WM9B]+
MW/PCC2P2,1B     6H/=GO\ G6_Z</\ CR*/<YG_ $W_ ,0_W$OSR/?]4?\
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MUX!JUA'N7#;9IMXT6YM57=T++"J[7PN7IVNC549)O:Y\D AXFL
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M[E%<\:E81EY[>*S?=-DGZNP@K-,BKN3B8Q6(J^R<U**JHB]',9 &TH
M%37WE7^._$K[U=N_.^ "^')O^K,>_#VOM)S/?G=_6F7OD]Y[>W*Q(NF46
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M'*N1'91LI$_3V-(L:HB^5':(ON[U1-R2[(&HJ4<CI51:QJ4BAI29<
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MVSG;1HMQ;HM$>B43MX*K5T3EIQ-JKH7*C7*K58]\I@A GL
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MJJO2ILE;V\%I;LM;5C8[:)C6,:U*-:UJ(C6M1-B(B(B(B;D/H#\C]@
M   "#'WA'V#:CZ?M>_BWGPLWRF]Z,GHJ?X2 JISB=TL?I>W^#N"D:-*#+D
M   W3\N3V\N(OT_:V_&2$(YU?[KL?]%7'P:DG:+][67?2]M\(TZ-HR"-HP
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M9/L,5AU,PJ/_ &*[X8+SA3UD[6TAE6G1+&WLW+L1'QMJJNE0K1BY12
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MOWM$9$[\,GC2T'*9DUV9-4&8W.SBP[!H'3N5?6]L]%BMVK]]57S-\,*^);R
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MXXHUK<6LS4M:UJ,U*6I1]3,_29B9$1&HC6I1$(155<JN<M7*?X'^G^
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MRG;C;DI*V,:IF9:]K&6VH>7LLL(-<J]P"*CME&HC4]2%U[B* VVY;[EAU:3
M\033S'Y:81=R5M'N79#.Y:K$JKN9.NUO0DW1[JJI2WFNT;7'\-74G+L5<9LX
MT2\8U-LUNU*),B)ODMTV.Z5@Z?<FHM/8:"F<
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ML6L9LY,<DJ3)CQ=3M&]8,*U0P5&2*R#-=M&GQF#=7<G;0HJJKH7+O2JNB<O
M^J*Q[\D-;M%<7TFQQ7Q(^?*%U(OQ6XWTWKV$ZHB(V9B;EHC96IQLHJ/9'&2)
MH(,                 _P!)2I:DI2DU*49)2E)&:E*,^A)21=3,S,_00*J(
ME5W'^HBJM$WEP_R5O*[M]&,1.6/(3'EUFU[^H=:U/@EHTI%EKG&[N(IF=D^1
MPG6TKK\WR*M?4PS$4?BUE>\XE\DR7UM1<^.8_6VWS.YV1,IS<>!12(MU.U?)
MN)&+5L<:IZZ&-R<2NW22(BMJQJ.?I#RQ:#W.5&-U"SC#V>8)HU2T@<GE6T;T
MHZ61JIY,\C5X49OBC5R.H]ZMCL7BH9<\     B&\U[RT:?G!KE&<8 Q!J.26
MMJ:86&6+O@Q8^P:%@I,]>M,@F.NL1XYR9KJW*B:^KPX,QU:7#1'DON(G[0G6
M6XTTQ=<,Q5729.O)$[9J558'K1OQAB(BJM$1$E8W:]B(J5>QJ+73F!T0MM4\
M%3%<(1D>=K*)>Q<M$2XC2KOBTCE5$2KE587NV1O54548]RI15R?&,CPK(KK$
M<OH[7&<HQNRETU_C]Y!D5EO3VL!Y4>97V,"6VU)B2HSR#2M"TD9&0T\LKVSQ
M*TCO\/ECFLIF(]DC'(YCVN2J.:Y*HJ*FY4,I+ZQO<+O)<.Q&*2"_@>K)(WM5
MKV/:M'-<U:*BHN]%/A#Z3Y               "RWY)GE?3\SR#&>9F_:!R)A
M&-3T6^CL'N8;[$G+LEKW4.5^RK:)+8018I02D^+3I(^ZPL&DR?1&804NFO,E
MK9%AUI-IUE65'8E,W@O9F*BI%&Y/*MVJB_RLB;)?Z.-59M>Y>SN_RO:$38G>
M0:F9NA5N%P/X[&!Z*BS2M6K;EZ*G\E&NV'^DD1'[&,3M+<HH,:)   !42\[C
MRQK;"LIR3F9H;&WYV Y3)E7F]\4J(YNO81E4M_QK#9,&*SU=<Q3*9#RGK;M2
M?R;8&Y)4HXTE10[^<M>M,&)6,.G6:9D;BL#4992O6B31(E&V[E78DL2)2+;[
MI'1B)QL3M,ZN:/0NXPR_GU,RE K\(N'*^_B8E5@E5:NN6HFU8I57BFV>YR5>
MJ\#U[.M8+CE(P             E!\KSR\<DYU;D9<OX=E5<?M>6$"=M;*V2=
MB?*I]2E1-=XY.)3:E9%D;*.C[K)F=9!4<A?1Q<9M^%-;=6[/3'+JMM7,DS7=
ML<VUB6B\/0MQ(W^CC7UJ+_*/\A-B/5L[Z#Z-WNJV94==M?'D^S>UUW*E4X^E
M+>-VSW21/7*G\DQ5>NU6(Z./,\?<Q+,,KQ5TUF[C.2WN/N&XMMQ9N4UI*KEF
MMQDB96LU1CZFCXIGZ2] E_#KM+_#X+YOK9H62?QVH[IV]/20MB=FN'8E<8>[
MUT$\D:[E]8Y6]&SHZ-AYH?8?"     7%_=O[@G^,>^,?\=]1UF]T7!QE=WJS
M17NO\3A$^UZ>WQY'W.]KG0NO:TCK^X,]N<&WX<Z87=T3R\+X*]*\$\JT7P)V
MFSQJ:2\E5SQ9%Q:SJON>+<=.A.TMXFU3PKV>WQ(6*144N817^==]F3R7_J:_
MS :I$X\MW?1@W][\QNB ^9_N,QS^Y_\ ,+0H'C5(R*       Z87%'V6^-?T
M Z<^KO'!C-GK_&^,^E;OSB0W"T^_P%@GHBS\WC,_#E3KS0/S3/L]N5WT5S_G
M.K$JZ'][.!?+F^U<1%KWW.Y@]'N]LTYW8UN,:P      .B)Y6?V>W%'Z*X'S
MG:#)'7#O9QWY<[VK39303N=R_P"CV^V<;^"*B72IK[RK_'?B5]ZNW?G? !?#
MDW_5F/?A[7VDYGOSN_K3+WR>\]O;E8D73*+     &_GE:?:$\4?I4K_FVS$5
MZW]TV._(7>V:2[H)WQ9?](-]JXZ(@R0-E         YR7F-^WERZ^G[9/XR3
M1K[I!W78!Z*M_@T,7-:.]K,7I>Y^$<:6"1B,0    "U![L]_SK?].'_'D4>Y
MS/\ IO\ XA_N)?GD>_ZH_P"&_P"_EJ 4=+\
M'\W6FI#3K#[3;S#S:VGF74)<:=:<2:'&G6UDI#C;B%&2DF1D9'T,?ZUSF.1S
M55'(M45-Z+UH?XYK7M5CT16JE%1=J*B]"E';SBO+:E\2-FO;GU11OJXX[1N9
M#S$>#'6J)JG-I[CLN5A4OP^Y,;'+3X[]&ZKM2ELG(9EW1VUOZ8<O>L4>?<%3
M+F.RI^U]C&B*KEVW4+:(DR=<C=C9DV[:2;GJC<L.9+1.33O'%S-E^)?V+OY5
M5$:FRTG=55@7JC=M= NRB<4>]B*^$P62*O
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MDY+,I+<8QBV=KAGN5M"VTA54V+)*J23*GWS&,C1?O9EZRVP*%&AH
M5-?>5?X[\2OO5V[\[X +X<F_ZLQ[\/:^TG,]^=W]:9>^3WGM[<K$BZ918
M  GX]W-]MO:7Z*^;_6WH\56YO>[6Q].0^:WI;KDO[T;_ - 3^=V)=(&<IIN
M    8+Y#<;=,\I]<V6K=WX36YCC$[N?A./H]7O,:MB:6U'R'%+QDDV./WL1*
MS)+["T^(VI3+R7&''&E]/E+..8LCXPS&\M7+[>];L6FUDC:U6.5B^3(Q?N7)
ML6CFJCD1R<IG+).6<_8*_ <TVK+FP?M;78^)]*))$]/*CD3H<U=J5:Y',5S5
MI_\ -WR-.0W'EZXS;0:++D-J"-ZQ-./40FRVWBE>W_">'>XC#2DLM:CH62?7
M*-#KKO8MUV#$;(:!::\S64LVMCPW-2LPC,"T;5ZK\5E=]Y*O\DJ[^"941*HU
MLLBF<>J7*KG+)KI,4RBC\9RXVKJ,:GQN)O5)"W^61-W' BJM%<Z*-I!U)C28
M4F1#F1WXDN(^[&E19+3C$F-)8<4T_'D,.I0ZR^RZ@TK0HB4E1&1EU%F&/9(Q
M)(U1T;D145%JBHNU%14V*BIN4JP]CXGK'(BMD:JHJ*E%14V*BHNU%1=BHNX_
M@/Z/X            E*X8>4=RKY@2*G(BQQ_3^G)AQY+VT]B5LV S:5CIDHW
M\$Q9SU6ZS5QUKN-E]OU>J4I)I7-;5T2<(ZC:^9&T^9):=LF(9A;5$MK=R.5K
MDZ)Y4JR&B[VKQ2]*1JFTGK3+EWS_ *COCO>Q7#<M.HJW5PUS4>U>F"):/GJF
MYR<,2THLJ+L+D/#'@1Q^X.88YC^I<?7-RRXB,,YKM'(TQIN<Y@ZT;;IL2I[3
M+3530-2$$N/60TM1&C22UDZ^:WUYXZBZIYKU,Q%+O'I>&PC<JPVT=4AB1=E4
M;55>]4V.D?5R[DX6T:FE&F>DF3]*\,6SR]#Q8A(U$GNI*.GF5-M%<B(C(T7:
MV)B(Q-Z\3ZN7=41P2>     4M_>,O;;U;^BOA'UM[P&C7*%W:WWIR;S6R,R.
M=#O1L/0$'G=\0#BU)44     E[\B_P"T?U%]ZNV?JVR00!S.=SV(?A[7SB,L
M9RJ=]6'?)[OS:0OBC+LUE   #P.S]6Z\W1@N1:SVIB--G&"Y7!<KKW'+V,;\
M.6POTMO,N-J:EU]C#>)+L67&<9EQ'T(=9<;=0E9>K@F-XMES%(<:P.XDML4@
M=Q,D8M%1>I=Z.:J;',<BM<U5:Y%:JH>1CN X-F?"9L#Q^WBNL)N&<,D<B5:J
M="HNQ6N:NUKVJCV.1'-<CD12GSSW\BW<.D)EUL7BM&N]VZCZO3W\)90F?M["
M(Y$IQR.BJB,,GL*I8/H3+U:T=F25=KL-26UR5Z":6<SF7LRQQX1GET6&X_L:
MDR^3:S+U\2JO8.7I21>SZ6R(JHQ,X=6^5/,F5I9<:R"V7%,N[7+ GE7D"=*<
M"(GQAB="QIVO0Z-419%@+EQ)4"5)@SHTB%.A2'HDR'+9<C2HDJ,XIF1&DQWD
MH>8D,/(-"T+(E)41D9$9"U$<C)6-EB<CHW(BHJ+5%1=J*BIL5%3:BIO*C21R
M0R.BE:K96JJ*BHJ*BHM%147:BHNQ47:BGYQ_1_            &8M)<?]S\C
MLRBX#I#7&3[&R>0MCQHF/UZW851'DNFRW8Y'=OFQ28Q4$Z7:J982(T5)^@W"
M/T#G\RYKRYD_#G8KF6\@L[)*T61U%>J)7AC8E7R/I["-KG+U'297RAF;.N)M
MPC*UE/>W[J52-M6L15HCI'K1D3*^SD<UJ=9;K\N'R3,(XUSZ/<_)211;2W=7
MNQ+;&,6@H7,UUK&Q94U)BSVCFL,N9CF5<^@E-S76FH,%[TQVG7&VIAT#U@YD
ML3SE%+EW)J2V.6GHK9)7;+BY:NQ6K15[*%R;%8BJ]Z>O<U%=&:*Z*\KV%9(F
MBS-G=T5_FEBH^*)OE6UJY**CDXD19IFKM1ZHC&+ZQKG-;(3YBK!;@
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M6     -_/*T^T)XH_2I7_-MF(KUO[IL=^0N]LTEW03OBR_Z0;[5QT1!D@;*
M       !SDO,;]O+EU]/VR?QDFC7W2#NNP#T5;_!H8N:T=[68O2]S\(XTL$C
M$8@    %J#W9[_G6_P"G#_CR*/<YG_3?_$/]Q+\\CW_5'_#?]_+4 HZ7X
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M+=[9()&HYKFJCFN:Y*HYJI5%145%146BIM0_8/S/T
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MD:C4PF1G>$1_CD23)*NF.D?H[NI]>TK-Y;YPZ-;%F_"*NV5ELY/LT@F7U?\
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MVGN3,RV>:<+O,9DQ"RF22-LLMLZ-7(BI1Z,M&.5-O0]J^$F:%=2RX
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MNJWQ+]H8+&'XAVW9_%F2LKV_9<?'VLTU:=BWAX>&E75K5*2[I7HOE;2'X_\
MLU<8A/\ I'L.T^,OA?P]AVW!P=E!#2O;.XN+BK1M*46N_@BHET
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M:BI'<1HOKF[^%[:HDL2JKHW*FUS',>[382&1J
M       6Q/(=\Q%R^@0^$&X;TW;>EARI?'S(+25WO6%%"9?G6^K'Y#QDXX_C
M\9IR92DI2S]0)^(DT-Q8C2J)<T6D:6LKM2\O14MY'(E_&U-C7JJ-9<HB=$BJ
MC)MWE\,BU5\CDT&Y3=977<+=+<R2UN(FJN'R.7:Z-J*Y]JJKTQHBOAW^Y\4:
M4;'&U;/@I27K
M
M
M
M
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MF<OQ:[:B]G,U/8NW]G,U/7Q*JJF]JO91RZ'"4")@
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MR)-G!.U$7C:F](YDI)'O1*NCXE=&Y3?D162X
M
M
M
M
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ME/)C6#))?Y)<ZJ2HE9;9%78RY:U-R>M;.B(QRTXDC<Y&K#L+"%;@
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MJ*;#03PW,++FW<U]O(U'-<U45KFN2K7-5-BHJ*BHJ;%0_:/S/U
M
M
M
M
M
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M7PMG%;*[?)9U1.!.M;=ZHWH]R?&UJ48Y2P^*DER0
M
M
M
M
M
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MM0R /)/8
M
M
M
M
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M"CKJSJNYBJB7$*=2->YLS&IM7CF=N0M"BDQ>\
M
M
M
M
M
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M"T7:G0M47:A[,><>F
M
M
M
M
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MO5J<#&(C$<YW B\2M1:<2HB4V/''G:@
M
M
M
M
M
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M*5\I5Z-GBV'2V>&X=A[>&PMX(&TI2-C6)15JJ>2B=.WQ[3T@^,^T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
<                                 #__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
